Sign In
Buy KYMR
$73.21
+1.92 (+2.69%)
At Close: Jun 03, 2026
Kymera Therapeutics Announces Pricing of $250 Million Public Offering
11:56pm, Thursday, 26'th Jun 2025
WATERTOWN, Mass., June 26, 2025 (GLOBE NEWSWIRE) -- Kymera Therapeutics, Inc. (NASDAQ: KYMR), a clinical-stage biopharmaceutical company advancing a new class of oral small molecule degrader medicines
KYMR Collaborates With GILD; Stock Down on Sanofi Deal Update
09:40am, Thursday, 26'th Jun 2025
Kymera's shares drop as Sanofi ends KT-474 development, but Gilead's oncology deal remains positive.
Kymera Therapeutics Announces Proposed Public Offering
04:05pm, Wednesday, 25'th Jun 2025
WATERTOWN, Mass., June 25, 2025 (GLOBE NEWSWIRE) -- Kymera Therapeutics, Inc. (NASDAQ: KYMR), a clinical-stage biopharmaceutical company advancing a new class of oral small molecule degrader medicines
Gilead partners with Kymera to develop novel cancer therapy
11:41am, Wednesday, 25'th Jun 2025
Gilead Sciences Inc (NASDAQ:GILD, ETR:GIS) and Kymera Therapeutics (NASDAQ:KYMR) have entered into an exclusive option and license agreement focused on developing a novel cancer treatment targeting cy
Gilead signs up to $750 million cancer drug deal with Kymera Therapeutics
09:15am, Wednesday, 25'th Jun 2025
Gilead Sciences has entered into an option and license deal with Kymera Therapeutics to support the development and sales of a class of cancer drugs, the companies said on Wednesday.
Kymera Therapeutics Announces Sanofi IRAK4 Collaboration Update
07:05am, Wednesday, 25'th Jun 2025
Sanofi to advance Kymera's next-generation oral IRAK4 degrader development candidate, KT-485, into clinical testing and will not advance KT-474
FOSTER CITY, Calif. & WATERTOWN, Mass.--(BUSINESS WIRE)--Gilead Sciences, Inc. (NASDAQ: GILD) and Kymera Therapeutics, Inc. (NASDAQ: KYMR), today announced that they have entered into an exclusive opt
Analysts Can't Get Enough of These Little-Known Biopharma Stocks
01:58pm, Thursday, 12'th Jun 2025
The biopharmaceuticals industry is both exciting and risky for investors. Many leading growth stocks in the U.S. market are found in this sector, due to the significant rallies that biopharmaceutic
Kymera Stock Gains on Positive Data on Investigational Dermatitis Drug
12:16pm, Tuesday, 03'rd Jun 2025
KYMR jumps after KT-621 phase I data beats expectations, matching or topping Dupixent on key biomarkers in Th2 diseases.
Kymera: Positive Phase 1 KT-621 Study Leads To Q4 2025 AD Treatment Data
02:55pm, Monday, 02'nd Jun 2025
Kymera Therapeutics' KT-621 demonstrated strong proof-of-concept as an oral STAT6 degrader, showing biologic-like efficacy in phase 1 healthy volunteer data. Results from phase 1b BroADen study, using
Phase 1 healthy volunteer data of KT-621, a once-a-day STAT6 degrader, surpass Kymera's target product profile, significantly derisking program and further validating its oral, biologics-like profile
Kymera Therapeutics to Announce KT-621 Phase 1 Healthy Volunteer Trial Results on June 2, 2025
04:01pm, Friday, 30'th May 2025
Company to host video webcast at 8:00 a.m. ET on Monday, June 2, 2025 Company to host video webcast at 8:00 a.m. ET on Monday, June 2, 2025
Kymera Therapeutics to Participate in Upcoming June Investor Conferences
07:00am, Thursday, 29'th May 2025
WATERTOWN, Mass., May 29, 2025 (GLOBE NEWSWIRE) -- Kymera Therapeutics, Inc. (NASDAQ: KYMR), a clinical-stage biopharmaceutical company advancing a new class of oral small molecule degrader medicines
KT-621, a potent, selective, oral STAT6 degrader, demonstrated comparable or superior activity to dupilumab in a newly disclosed preclinical chronic asthma model reversing disease progression
Kymera Therapeutics: Intriguing Degradation Thesis, But A Bit Powder Puff
04:59pm, Wednesday, 14'th May 2025
I'm downgrading Kymera to 'Hold' due to slow clinical progress, pipeline uncertainty, and lack of near-term catalysts despite strong cash position. Kymera's unique focus on immunology with oral protei
